NSCLC: Brain and leptomeningeal metastases; Milestone analysis of trials submitted for drug approvals

Speaker: Tanja Cufer

Tanja Cufer discusses the abstracts presented in lung cancer track at ASCO 2016 Annual Congress. Due to treatment advances and longer lifespan in NSCLC patients with oncogene-driven disease, brain and leptomeningeal metastases are nowadays often. She discusses the efficacy results from several newer agents in that setting. In addition, she discusses the results with a new antibody-drug conjugate in metastatic setting, as well as milestone analyses with immune checkpoint inhibitors, targeted therapy and standard therapy in trials submitted to the US FDA.

Discussion Points

  1. Rationale for the study
  2. Key study findings
  3. Practice perspective

Abstract 9009: Safety and efficacy of lorlatinib (PF-06463922) from the dose-escalation component of a study in patients with advanced ALK+ or ROS1+ non-small cell lung cancer (NSCLC).                                                                                           

Abstract 9002: Osimertinib activity in patients (pts) with leptomeningeal (LM) disease from non-small cell lung cancer (NSCLC): Updated results from BLOOM, a phase I study.                                                                                      

Abstract 9003: Phase I study of AZD3759, a CNS penetrable EGFR inhibitor, for the treatment of non-small-cell lung cancer (NSCLC) with brain metastasis (BM) and leptomeningeal metastasis (LM).

Abstract  9011: Therapy of metastatic, non-small cell lung cancer (mNSCLC) with the anti-Trop-2-SN-38 antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132).                                                                           

Abstract 9010: Milestone analyses with immune checkpoint inhibitors (ICI), targeted therapy (TT), and standard therapy in metastatic non-small cell lung cancer (mNSCLC) trials submitted to the U.S. FDA: An updated pooled analysis.